Stock listing

Exelixis, Inc.

Selected listing: EX9 · DUS · EUR · DE

Exelixis, Inc. (Dusseldorf:EX9), Health Technology. Latest release Aug 31, 2026: Exelixis Announces Update on Patent Litigation Trial Appeal with MSN…

EX9:DUSEURDEUpdated October 2, 2026

Ticker: Dusseldorf:EX9
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Dusseldorf
Currency: EUR

About Exelixis, Inc.

Exelixis, Inc. is a publicly traded biotechnology company based in the United States, focused on developing and commercializing innovative therapies for cancer treatment. Exelixis aims to improve the lives of patients through its advanced research and development efforts in oncology.

Latest news from Exelixis, Inc.

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

August 31, 2026

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 5, 2026

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

July 22, 2026

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

June 21, 2026

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

May 29, 2026

All Exelixis, Inc. news →

Events

Replays

Exelixis, Inc. (EXEL) Q2 2026 Earnings Call
Wed, Aug 05, 2026 · 05:00 PM ET
Watch
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call
Tue, May 05, 2026 · 05:00 PM ET
Watch
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call
Tue, Feb 10, 2026 · 05:00 PM ET
Watch

Research Exelixis, Inc.

Exelixis, Inc. company profile

View the public company page for Exelixis, Inc. on 6ix.

Exelixis, Inc. news

Read company news and market updates connected to Exelixis, Inc..

Exelixis, Inc. investor events

Find investor webinars, events, and replay context for Exelixis, Inc..